ExpressCells

ExpressCells is pleased to announce we will be sponsoring a Round Table at the 7th Annual SBI2 High Content 2020 Virtual Conference. Join us for High Content Screening: Optimizing Multi-Parametric, Cell-Based Assays on September 17th, 4:00pm EDT.

ExpressCells leverages proprietary gene-editing tools and the power of CRISPR to create custom, knock-in cell lines for drug discovery, toxicology, and other biologic research. We invite you to visit our Catalog page to learn more about our Reporter Cell Lines and our two new Overexpression catalog items to support research into COVID-19.

Joe Fetterman sat down with Matt Handel, the CEO of ExpressCells, to engage in a discussion about his time in the entrepreneurial space, his desire to make a difference in the lives of patients, and how his time at previous jobs inspired him to become involved in business []

ExpressCells is pleased to offer the following NEW catalog items in support of COVID-19 research, both in HEK293T cells: (1) SARS-CoV-2 nucleocapsid protein (heterozygous) and (2) SARS-CoV-2 nucleocapsid protein (homozygous). To learn more and to see our Overexpression Cell Line Catalog, please click the button below.

ExpressCells is honored to be highlighted as a leader in innovation within Philadelphia’s robust biotech industry. ExpressCells is dedicated to improving drug development and biological research through the creation of better cell lines. As the biotech industry continues to gain traction nationwide, nowhere is this growth more apparent than in Philadelphia. Like many tech hubs, []

Attending BIO Digital Week? Be sure to check out ExpressCells’ presentation at Start-Up Stadium. You can also meet with ExpressCells through the One-on-One Partnering system. #BIODigital

To speed the production of knock-in cell lines, ExpressCells has developed FAST-HDR, a plasma vector system that leverages the power of CRISPR-Cas9. It can cut production times as much as 75%. Click to read article: Genetically Edited Cell Lines Enter the Fast Lane